Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$450K Buy
1,790
+126
+8% +$27.1K ﹤0.01% 80
2026
Q1
$362K Buy
1,664
+201
+14% +$44.6K ﹤0.01% 80
2025
Q4
$334K Buy
1,463
+149
+11% +$33.9K ﹤0.01% 76
2025
Q3
$304K Buy
1,314
+152
+13% +$31K ﹤0.01% 78
2025
Q2
$216K Buy
+1,162
New +$216K ﹤0.01% 80

Other funds holding ABBV

Acorns Advisers's ABBV Position: Q2 2026 in Review

Acorns Advisers increased its AbbVie (ABBV) stake by 7.6% in Q2 2026, buying an estimated $27.1K and bringing the position to 1,790 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #80.

Acorns Advisers first reported a position in ABBV in Q2 2025 and has held it in 5 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Acorns Advisers held 1,790 shares of AbbVie worth $450K as of Q2 2026.
  • Acorns Advisers bought 126 AbbVie shares in Q2 2026, an estimated $27.1K.
  • AbbVie made up ﹤0.01% of Acorns Advisers's portfolio in Q2 2026, its #80 holding.
  • Acorns Advisers first reported a position in AbbVie in Q2 2025 and has held it in 5 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Acorns Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.